{"id":40290,"date":"2025-08-28T15:01:35","date_gmt":"2025-08-28T07:01:35","guid":{"rendered":"https:\/\/flcube.com\/?p=40290"},"modified":"2025-08-28T15:01:35","modified_gmt":"2025-08-28T07:01:35","slug":"anglikang-secures-exclusive-rights-to-yafeis-imd%e2%80%911005-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40290","title":{"rendered":"Anglikang Secures Exclusive Rights to Yafei\u2019s IMD\u20111005 in China"},"content":{"rendered":"\n

Zhejiang Anglikang Pharmaceutical Co., Ltd. (SHE: 002940<\/a>) announced that it has entered into a license agreement<\/strong> with Yafei (Shanghai) Biomedical Technology Co., Ltd.<\/strong> and its subsidiary Affinity Biopharmaceutical Co., Ltd.<\/strong> The agreement grants Anglikang exclusive rights to research, develop, manufacture and commercialise<\/strong> the IMD\u20111005<\/strong> TMEAbody in China, including mainland, Hong\u202fKong, Macau and Taiwan<\/strong>.<\/p>\n\n\n\n

Deal Highlights<\/h3>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
License Scope<\/strong><\/td>Exclusive R&D, production & commercialization of IMD\u20111005<\/strong> in China<\/td><\/tr>
Upfront Payment<\/strong><\/td>RMB\u202f150\u202fmillion<\/strong> paid in staged instalments to Yafei & Affinity<\/td><\/tr>
Milestone Payments<\/strong><\/td>Up to RMB\u202f620\u202fmillion<\/strong> tied to R&D and sales milestones<\/td><\/tr>
Royalty<\/strong><\/td>12.8\u202f%<\/strong> of net sales during the royalty period<\/td><\/tr>
Target<\/strong><\/td>CD47\u2011targeting Tumour Micro\u2011Environment\u2011Activated Antibody (TMEAbody)<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

About IMD\u20111005<\/h3>\n\n\n\n